Greaves discusses a new study in that takes us closer to being able to adopt a pharmacogenetic approach to reduce bleeding risk from coumarin therapy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1261512PMC
http://dx.doi.org/10.1371/journal.pmed.0020342DOI Listing

Publication Analysis

Top Keywords

pharmacogenetics management
4
management coumarin
4
coumarin anticoagulant
4
anticoagulant therapy
4
therapy forward
4
forward expensive
4
expensive diversion?
4
diversion? greaves
4
greaves discusses
4
discusses study
4

Similar Publications

4P medicine (personalized, preventive, predictive, and participatory) is experiencing a remarkable rise, and pharmacogenetics is an essential part of it. However, several obstacles are hindering its deployment. This round table brought together a group of experts to take stock of the situation, reflecting on ways to facilitate the prescription of these tests and the dissemination of the results on a national scale.

View Article and Find Full Text PDF

Hypoparathyroidism: Similarities and differences between Western and Eastern countries.

Osteoporos Int

January 2025

Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Backgroud: Hypoparathyroidism (hypoPT) is characterized by acute and chronic complications due to insufficient parathyroid hormone (PTH) production or action. Several management guidelines have been developed, but mostly based on evidence from Western countries. Data from Eastern countries have not been systematically compared with those from Western countries.

View Article and Find Full Text PDF

Objective: Several studies have attempted to identify genetic determinants of clinical response to opioids administered during labor or after cesarean section. However, their results were often contrasting. A systematic review and meta-analysis was conducted to quantitatively assess the association between gene polymorphisms and clinical outcomes of opioid administration in the treatment of labor pain and post-cesarean pain.

View Article and Find Full Text PDF

Background: Tacrolimus is widely used as a first-line immunosuppressant in transplant immunology; however, its clinical application is constrained by the narrow therapeutic index and considerable interindividual variability. In this study, we identified the potential regulatory role of a novel promoter polymorphism, rs4519508 C > T, in the tacrolimus pharmacodynamic pathway.

Methods: Dual-luciferase reporter assays and bioinformatic analysis were applied to assess the impact of allelic variation.

View Article and Find Full Text PDF

Integration of pharmacogenetic data in epic genomic module drives clinical decision support alerts.

Front Pharmacol

December 2024

Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL, United States.

Introduction: The Precision Medicine Program (PMP) at the University of Florida (UF) focuses on advancing pharmacogenomics (PGx) to improve patient care.

Methods: The UF PMP, in collaboration with the UF Health Pathology Laboratory (UFHPL), utilized Health Level Seven (HL7) standards to integrate PGx data into Epic's Genomic Module to enhance the management and utilization of PGx data in clinical practice.

Results: A key feature of the Genomic Module is the introduction of genomic indicators-innovative tools that flag actionable genetic information directly within the electronic health record (EHR).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!